Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD)

Inclusion Criteria

• •Subject has active Crohn's disease (as determined by treating gastroenterologist)
• •Age ≥ 18 years old
• •Commencing treatment with adalimumab according to product label (at the discretion of their responsible gastroenterologist)
• •Willing to attend scheduled protocol visits, complete required study procedures and able to fast overnight
• •No previous treatment with anti-TNF therapies or other biological therapies (i.e., cytokines), including investigational agents